
Caribou Biosciences (CRBU) Stock Forecast & Price Target
Caribou Biosciences (CRBU) Analyst Ratings
Bulls say
Caribou Biosciences is projected to have a market value of $1.05B, translating to a 12-month price objective of $11 per share. This is based on a DCF model using a 10% discount rate, a 1.0% terminal growth rate, and an effective tax rate of 29.84%, with a 60% probability of approval for vispa-cel (CB-010) and a 35% probability of approval for CB-011. However, risks to this valuation include negative clinical results, delays in advancing candidates, failure to achieve favorable clinical results with other pipeline candidates, regulatory approval challenges, and competition.
Bears say
Caribou Biosciences is facing significant risks due to negative clinical results and delays in advancing their lead assets, CB-010 and CB-011, into registration programs. These risks are compounded by potential failures to achieve favorable clinical results with other pipeline candidates and the potential inability to obtain timely regulatory approvals. The company's 11% discount rate and 1.0% terminal growth rate in the DCF-based valuation suggests a lack of confidence in the company's potential for future growth.
This aggregate rating is based on analysts' research of Caribou Biosciences and is not a guaranteed prediction by Public.com or investment advice.
Caribou Biosciences (CRBU) Analyst Forecast & Price Prediction
Start investing in Caribou Biosciences (CRBU)
Order type
Buy in
Order amount
Est. shares
0 shares